Study guide

15.1 Determining Required Formulations

APC Intern Written Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Pathway to General Registration 1.3 Restricted Open-Book Strategy (AMH & APF) 1.4 Scoring, Results & Appeals

2 Legal Framework: PBS & Medicine Schedules

2.1 PBS, Authority Prescriptions & Special Access Scheme 2.2 Schedules 2 & 3 (Pharmacy & Pharmacist Only Medicines) 2.3 Schedules 4 & 8 (Prescription Only & Controlled Drugs)

3 Legal Framework: Privacy, National Law & Pharmacy Board

3.1 Privacy, Confidentiality & Patient Rights 3.2 Health Practitioner National Law & Registration 3.3 Pharmacy Board Codes, Guidelines & Standards

4 Patient-Centred Medication Management

4.1 Assessing Clinical Situations & Treatment Options 4.2 Patient Factors: Adherence, Efficacy & Safety 4.3 Drug & Dosage-Form Factors 4.4 Culturally Responsive Medication Management

5 Primary Care & Judicious Use of Medicines

5.1 Primary Care & OTC Assessment 5.2 Judicious Use of Antimicrobials & High-Risk Agents 5.3 Non-Pharmacological Options & Evidence-Based OTC Choices

6 Dispensing & Clinical Appropriateness

6.1 Prescription Evaluation 6.2 Clinical Appropriateness Checks 6.3 Labelling, Packaging & Dispensing Standards 6.4 Communicating with Prescribers & Documenting Changes

7 Counselling & Acute Care

7.1 Patient-Centred Counselling 7.2 Confirming Understanding & Lifestyle Counselling 7.3 Acute Illness, Injury & Emergency Response

8 Therapeutics: Cardiovascular & Endocrine

8.1 Hypertension & Heart Failure 8.2 Ischaemic Heart Disease & Anticoagulation 8.3 Diabetes Medicines 8.4 Thyroid & Lipid Disorders

9 Therapeutics: Infection, Respiratory & Gastrointestinal

9.1 Anti-Infectives & Infection Management 9.2 Asthma & COPD 9.3 Gastrointestinal & Hepatic Conditions 9.4 Vaccination & Travel Health

10 Therapeutics: Neurology, Psychiatry & Pain

10.1 Epilepsy & Movement Disorders 10.2 Depression, Anxiety & Psychosis 10.3 Pain Management & Opioids 10.4 Migraine & Common Analgesics

11 Therapeutics: Special Populations & Systems

11.1 Women's Health, Contraception & Pregnancy 11.2 Dermatology, Ophthalmology & ENT 11.3 Renal/Hepatic Impairment & Dose Adjustment

12 Therapeutics: Rheumatology, Haematology, Urology, Oncology & Toxicology

12.1 Rheumatology: Gout, Osteoarthritis & Inflammatory Arthritis 12.2 Haematology: Anaemias & Blood Safety Monitoring 12.3 Urology & Men's Health 12.4 Oncology Support & Oral Anticancer Medicines 12.5 Toxicology & Poisoning Management

13 Monitoring: Clinical Review

13.1 Clinical Review Process 13.2 Interpreting Laboratory & Clinical Monitoring 13.3 Recommending Treatment Modifications

14 Monitoring: Safety & Adverse Drug Reactions

14.1 Adverse Drug Reactions & Reporting 14.2 Allergies, Sensitivities & Cross-Reactivity 14.3 High-Risk Medicines Monitoring

15 Compounding Medicines

15.1 Determining Required Formulations 15.2 Compounding Standards & Quality 15.3 Patient-Specific Preparations

16 Pharmaceutical Calculations

16.1 Dosage Calculations 16.2 Concentrations, Dilutions & Alligation 16.3 Half-Life & Basic Kinetic Calculations

17 Promote Health & Well-Being

17.1 National & Local Health Priorities 17.2 Screening Programs & Pharmacist Role 17.3 Culturally Responsive Promotion & Self-Sufficiency

15.1 Determining Required Formulations

Key Takeaways Explain This Topic AI

Compound only when a commercial product cannot reasonably meet the clinical need; proprietary medicines are preferred for quality, stability, and consistency when suitable.

The Australian Pharmaceutical Formulary and Handbook (APF) is the primary open-book reference for standard formulations, compounding principles, beyond-use dating concepts, and labelling expectations.

Common justified indications include paediatric liquids, dermatological preparations, allergen-free or excipient-restricted products, and modified doses or strengths not commercially available.

Assign beyond-use dates using APF guidance and product-specific stability knowledge; BUD is not the same as a manufacturer’s expiry on an unopened proprietary pack.

Classify risk (simple vs complex) and sterile vs non-sterile scope before compounding; interns must know limits of competence and when referral or specialist facilities are required.

Last updated: August 2026

14.1 Determining Required Formulations

Quick Answer: Under Standard 3.4 , first decide whether compounding is needed at all . Prefer a commercially available proprietary product when it meets the clinical need. If compounding is justified, select a formulation using the Australian Pharmaceutical Formulary and Handbook (APF) and other evidence-based sources, check suitability (dose form, stability, patient factors), assign a beyond-use date (BUD) and storage conditions, and match the task to simple vs complex risk and sterile vs non-sterile capability. The Intern Written Examination is restricted open-book with APF (and AMH)—know where formulation, quality, and labelling guidance lives.

Compounding is the preparation of a medicine for an individual patient when a ready-made product is unsuitable or unavailable. It is a core pharmacist competency, but it is not a default solution. Every compounding decision starts with a clinical and practical filter: Is there a safer, more consistent commercial option?

  • When compounding is appropriate vs when proprietary products are preferred
  • Prefer proprietary products when they are suitable

Proprietary (commercial) medicines are manufactured under Good Manufacturing Practice (GMP) , with validated processes, shelf-life data, and consistent content uniformity. For the exam and practice, treat commercial availability as a quality and safety advantage , not only a convenience.

Prefer a proprietary product when:

The required drug, strength, and dose form are already on the Australian market and clinically appropriate

A different but therapeutically equivalent commercial option can meet the goal (for example an oral liquid vs crushing tablets when a licensed liquid exists)

The request is mainly for preference (flavour, colour, “natural” base) without a clinical barrier to the commercial product

  • The pharmacy lacks facilities, equipment, or competency for the complexity requested
  • When compounding is often justified

Clinical need Typical examples Intern reasoning

No suitable commercial form Oral liquid of a solid-only medicine for a child Dose form must match ability to take medicine

Dose not available Intermediate strength, weight-based titration Avoid unsafe splitting/crushing when precision needed

Excipient exclusion Dye-, gluten-, lactose-, or alcohol-free need Document the allergen/intolerance clearly

Dermatological customisation Dilution of a potent corticosteroid cream; combination topicals where evidence and stability allow Balance efficacy, irritation risk, and stability

Temporary supply disruption Short-term compounding during shortage with clinical urgency Prefer return to proprietary supply when restored

Special populations Paediatric, palliative, dysphagia, some veterinary (scope/policy dependent) Confirm legal/ethical scope for humans vs animals

Exam trap: A prescriber request alone does not make compounding mandatory. You still assess clinical necessity, formulation suitability, legal schedule, and whether a commercial product exists. If a licensed product fits, recommend it and document the rationale.

The APF as the key open-book formulation reference

For the APC Intern Written Examination you may bring one paper APF . Use it as your operational handbook for compounding—not as optional background reading.

What to look up in the APF under time pressure

Standard formulae for common non-sterile preparations (solutions, suspensions, creams, ointments, pastes, powders)

  • General compounding principles (weighing, measuring, mixing order, bases, vehicles)
  • Stability and beyond-use dating guidance for compounded preparations
  • Labelling requirements and advisory statements for compounded medicines
  • Quality and hygiene expectations linked to professional standards

When a standard APF formula exists for the requested preparation (or a closely related template), prefer that validated community-practice formula over inventing proportions from memory. If the APF has no formula, you may need primary literature, manufacturer stability data, hospital formularies, or referral to a specialist compounding service—do not improvise high-risk recipes under exam or practice pressure.

  • Linking APF use to AMH
  • AMH : clinical suitability of the drug (indication, dose, interactions, cautions, paediatric notes)
  • APF : how to prepare an appropriate formulation safely and label it

Both books together answer: Should this patient receive this drug, and if so in which compounded form with what BUD?

  • Suitability of formulation types
  • Paediatric liquids

Children often need oral liquids because of age, taste, or inability to swallow solids. Suitability checks include:

Accurate dose concentration so measuring devices deliver practical volumes (avoid extreme concentrations that force tiny or huge volumes)

Excipients : alcohol content, sugar (dental/metabolic concerns), propylene glycol in neonates, colourants, and known allergens

  • Palatability and adherence without compromising stability
  • Whether a commercial paediatric product already exists for the same drug

Reconstituting a proprietary antibiotic powder according to the product information is not the same as designing a novel compound from raw powder—see Section 15.3. Both need correct diluent, volume, storage, and expiry, but risk and documentation differ.

Dermatological preparations

Topical compounding is common (dilutions, combinations, alternative bases). Suitability includes:

  • Potency after dilution (especially corticosteroids)—document the final percentage and base
  • Base selection (cream vs ointment vs gel) for site, occlusion, and patient preference
  • Incompatibilities between actives or between active and base
  • Irritancy and infection risk on broken skin
  • Allergen-free and excipient-restricted products

When a patient has a documented allergy or intolerance to an excipient in the commercial product, compounding may be justified if the allergen cannot be avoided another way. Document the specific excipient problem. Do not compound solely because a patient dislikes an inactive ingredient without clinical significance.

Modified dose or strength

Modified strengths are common in titration, palliative care, and paediatrics. Confirm the prescribed strength is interpretable (mg/mL vs % w/w vs ratio), calculable, and measurable with available equipment. Prefer strengths that reduce calculation and measurement error.

Stability and beyond-use dating (high-level)

Expiry date on a manufacturer’s pack applies to the unopened proprietary product under stated storage. A beyond-use date (BUD) is the date after which a compounded preparation should not be used. BUD assignment is a professional responsibility informed by:

  • APF guidance for preparation type (aqueous oral liquid, topical cream, non-aqueous solid, etc.)
  • Known chemical, physical, and microbiological stability of ingredients
  • Water activity and contamination risk
  • Packaging (light-protective, airtight) and storage (room temperature, refrigerate)
  • Whether the preparation is multi-dose and how it will be handled at home

Principles for interns:

Aqueous preparations generally carry shorter BUDs than anhydrous solids or many non-aqueous topicals because of microbial risk

Refrigeration may extend usability for some preparations but can worsen physical instability for others—follow APF/product-specific guidance

“Looks fine” is not a stability test; appearance alone does not prove chemical potency

If stability data are poor and clinical need is non-urgent, prefer commercial alternatives or specialist compounders with documented formulas

Always state storage conditions with the BUD on the label and in counselling.

Risk assessment: simple vs complex compounding

Australian professional guidance distinguishes levels of compounding risk. For exam purposes, use a practical risk lens:

  • Factor Lower complexity (often “simple”) Higher complexity (“complex”)
  • Formula Standard APF formula, few ingredients Novel multi-ingredient, modified-release aims
  • Calculations Straightforward proportions Multi-step, very low doses, potent actives
  • Hazard Ordinary oral/topical actives Cytotoxics, hormones, sensitising powders, hazardous drugs
  • Environment Clean bench, standard PPE Dedicated rooms, containment, specialised HVAC

Sterility Non-sterile Sterile products for injection, eye, etc.

Population Older child/adult oral liquid Neonates, intrathecal, ophthalmic, implants

Simple non-sterile compounding (for example many APF creams, simple solutions/suspensions) may be within community pharmacy competence when procedures, equipment, and training are adequate. Complex compounding (hazardous drugs, advanced dosage forms, high-risk populations, sterile production) requires specialised facilities, training, and quality systems. Interns must recognise when not to proceed and when to refer.

Sterile vs non-sterile scope awareness

Non-sterile compounding : oral liquids, capsules, creams, ointments, some ear preparations (as appropriate), powders—subject to hygiene and BUD rules

Sterile compounding : injections, infusions, many ophthalmic preparations, irrigations for sterile body sites—requires aseptic technique, validated cleanrooms/equipment, and quality assurance beyond routine community dispensing

Most community intern experience is non-sterile . Questions may still test whether you recognise that sterile products are out of scope for an ordinary bench without aseptic facilities. Never “approximate” sterility for injections or eye drops by ordinary mixing.

Decision pathway for the exam

Confirm the clinical indication and legal supply pathway (prescription, schedule).

Search for a suitable proprietary product (including alternative strengths/forms).

If compounding is needed, open APF for formula, method notes, BUD concepts, and labelling.

Check patient factors (age, allergies, ability to measure doses).

Classify risk (simple/complex; sterile/non-sterile) and competence/facilities .

Only then compound—or refer/decline with a clear alternative plan.

Putting it together for the exam

Standard 3.4 rewards systematic formulation decisions. Show that you default to commercial quality , use APF deliberately under open-book conditions, justify paediatric and dermatological compounds by need, apply BUD and storage thinking, and escalate complex or sterile work appropriately.